Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Tax Provisions (2024 - 2025)

BridgeBio Pharma's Tax Provisions history spans 2 years, with the latest figure at -$120000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 110.41% year-over-year to -$120000.0; the TTM value through Dec 2025 reached -$512000.0, changed N/A, while the annual FY2025 figure was $435000.0, 62.27% down from the prior year.
  • Tax Provisions for Q4 2025 was -$120000.0 at BridgeBio Pharma, up from -$1.5 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.2 million in Q4 2024 and bottomed at -$1.5 million in Q3 2025.